Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

6.180
+0.2704.57%
Volume:11.92M
Turnover:73.47M
Market Cap:9.12B
PE:-86.47
High:6.340
Open:5.820
Low:5.820
Close:5.910
52wk High:13.150
52wk Low:2.030
Shares:1.48B
HK Float Shares:1.48B
Volume Ratio:1.16
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.071
ROE:-96.36%
ROA:-16.93%
PB:25.57
PE(LYR):-86.47
PS:39.78

Loading ...

CSTONE PHARMA-B Receives FDA Clearance for Phase II Trial of CS2009

Stock News
·
Feb 20

CStone Pharmaceuticals (HKEX: 2616) Announces U.S. FDA IND Clearance for Phase II Trial of CS2009 Trispecific Antibody

Bulletin Express
·
Feb 16

CStone Pharmaceuticals' CS2009 Tri-Specific Antibody Phase II Trial Receives FDA Clearance

Stock News
·
Feb 16

CStone Pharmaceuticals Receives FDA Clearance for Phase II Trial of CS2009

Reuters
·
Feb 16

CStone Pharmaceuticals - FDA Clears Ind Application for Cs2009 Phase Ii Trial

THOMSON REUTERS
·
Feb 16

CStone Pharmaceuticals (2616) Updates Joint Company Secretary Qualification and Announces Personnel Changes

Bulletin Express
·
Feb 06

CStone Pharmaceuticals-B Receives Exchange Approval for Company Secretary Qualification

Stock News
·
Feb 06

CStone Pharmaceuticals Appoints Weicong Ni as Sole Company Secretary

Reuters
·
Feb 06

BRIEF-Cstone Pharmaceuticals's CEO Buys Aggregate Of 976,000 Shares From Nov 2025 To Jan 2026

Reuters
·
Jan 27

CSTONE PHARMA-B (02616) CEO & Executive Director Dr. Yang Jianxin Purchases Additional 976,000 Shares, Cumulative Holdings Reach 12.477 Million Shares

Stock News
·
Jan 27

CStone Pharmaceuticals - CEO Buys Aggregate of 976,000 Shares From Nov 2025 to Jan 2026

THOMSON REUTERS
·
Jan 27

CStone Pharmaceuticals (SEHK:2616) Valuation After New Equity Awards And Board Changes

Simply Wall St.
·
Jan 26

CStone Pharmaceuticals (2616) Announces Grant of 15.72 Million Share Options and 8.06 Million RSUs

Bulletin Express
·
Jan 23

CSTONE PHARMA-B (02616) Grants 15.7155 Million Share Options and 8.055 Million Restricted Share Units

Stock News
·
Jan 23

CSTONE PHARMA-B (02616): Yan Jiaxun Appointed as Independent Non-Executive Director

Stock News
·
Jan 21

CStone Pharmaceuticals Files Director List with HKEX

Reuters
·
Jan 21

CStone Pharmaceuticals Appoints Catherine Yen as Independent Non-Executive Director

Reuters
·
Jan 21

Is CStone Pharmaceuticals (SEHK:2616) Turning Sugemalimab Data Into a Sustainable Immuno-Oncology Edge?

Simply Wall St.
·
Jan 13

CStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%

Stock News
·
Jan 07

CSTONE PHARMA-B (02616) Receives Further Investment from GIC! Stake Rises to 8.06%

Stock News
·
Dec 30, 2025